SOMATONORM 4 IU ▼

PRESCRIBING INFORMATION

PRESENTATION
A vial of sterile lyophilised powder of somatrem corresponding to 4 IU of human somatotropin (also containing aminoacetic acid and sodium phosphate as stabilisers) and supplied with a 2 ml ampoule of water for injections for use in the reconstitution of the injection.

USES
The treatment of short stature caused by decreased or absent secretion of pituitary growth hormone. The diagnosis should be verified by appropriate investigations of pituitary function by a specialist medical practitioner.

DOSAGE AND ADMINISTRATION
Route of administration:
By intramuscular injection.

Recommended dosage:
The dosage should be calculated according to the patient's body weight. Generally a dose of 0.5 IU/kg body weight per week is recommended. This weekly dose should be divided into 2 or 3 intramuscular injections.

PREPARATION OF SOLUTION
The solution is prepared by adding 2 ml of water for injections to the lyophilised substance in the vial. Gently dissolve the drug with a slow swirling motion. Do not shake vigorously as this may cause denaturation of the active ingredient.

CONTRA-INDICATIONS, WARNINGS, ETC.
Only patients with unfused epiphyses should be treated. Diabetes mellitus.

Precautions:
Patients treated with Somatonorm should be regularly assessed by a specialist in child growth. This assessment should include determination of growth response and endocrinological status, as relative deficiencies of other pituitary hormones may be exposed or exacerbated by an adequate growth response.

Overdosage:
Acute overdosage is unlikely and does not represent a hazard to the patient. The consequences of long term administration of doses above the normal therapeutic range are unknown.

Side-effects:
Clinical experience with Somatonorm is limited and recipients may develop antibody to growth hormone and E. coli protein. However, as with pituitary derived hormone, only in very rare instances has growth retardation occurred. No other adverse reactions have been noted.

PHARMACEUTICAL PRECAUTIONS
Store at 2–8°C. Reconstituted Somatonorm may be stored in the refrigerator for 24 hours before use.

LEGAL CATEGORY
POM.

PACKAGE QUANTITIES
Combined package containing one vial of somatrem 4 IU and one ampoule of 2 ml water for injections.

FURTHER INFORMATION
Somatonorm is produced using recombinant DNA technology. Somatrem is the British Approved Name for methionyl human somatotropin.

PRODUCT LICENCE NUMBER
0022/0060 P.A. 187/28/1

N.H.S. Price £ 28



INTERNATIONAL PAEDIATRIC HAEMATOLOGY UPDATE

March 12th–13th 1987
The Albany Hotel, Glasgow

Presentation on

Thalassaemia and Haemolytic Anaemias, Gene Probes, Leukaemias, Bone Marrow Transplants in Childhood, Coagulation Disorders

SPEAKERS

Dr. S. M. Andrew	Ontario	Dr. K. Hugh-Jones	London
Professor A. Bellingham	London	Dr. E. Letsky	London
Dr. A Burnett	Glasgow	Dr. J. Lilleyman	Sheffield
Dr. J. Chessells	London	Dr. S. Malcolm	London
Dr. S. Davis	London	Dr. G. Morgan	London
Dr. O. B. Eden	Edinburgh	Dr. A. Pettigrew	Glasgow
Dr. D. I. K. Evans	Manchester	Dr. G. Prentice	London
Dr. B. Gibson	Glasgow	Dr. C. Shiach	Glasgow
Dr. I. Hann	Glasgow	Dr. R. Stevens	Manchester
Dr. F. Hill	Birmingham	Professor D. J. Weatherall	Oxford

Further information and registration forms available from:

Dr. I. Hann, Department of Haematology, Royal Hospital for Sick Children, Yorkhill, Glasgow G3 8SJ

Lederle

This Symposium is being supported by Lederle Laboratories as a Service to Medicine

This publication is available in microform.

University Microfilms International reproduces this publication in microform: microfiche and 16mm or 35mm film. For information about this publication or any of the more than 13,000 titles we offer, complete and mail the coupon to: University Microfilms International, 300 N. Zeeb Road, Ann Arbor, MI 48106. Call us toll-free for an immediate response: 800-521-3044. Or call collect in Michigan, Alaska and Hawaii: 313-761-4700.

☐ Please send information about these titles:

Name _____

Company/Institution _____

Address _____

City _____

State _____ Zip _____

Phone (___) _____

University Microfilms International

Abbreviated Prescribing Information
'HUMULIN' S ▼ 'HUMULIN' I ▼ 'HUMULIN' Zn ▼ 'HUMULIN' M1 ▼ 'HUMULIN' M2 ▼ Human insulin (crb) **Presentation: Humulin S:** A sterile, aqueous solution of human insulin (crb). **Humulin I:** A sterile suspension of isophane human insulin (crb). **Humulin Zn:** A sterile suspension of crystalline human insulin (crb) zinc suspension. **Humulin M1:** A sterile suspension of human insulin (crb) in the proportion of 10% soluble insulin and 90% isophane insulin. **Humulin M2:** A sterile suspension of human insulin (crb) in the proportion of 20% soluble insulin and 80% isophane insulin. Each presentation contains 100 IU/ml. **Uses:** For the treatment of insulin-dependent diabetes mellitus. **Dosage and Administration:** The dosage should be determined by the physician, according to the requirements of the patient. Humulin S may be administered by subcutaneous, intramuscular or intravenous injection. Humulin I, Humulin Zn, Humulin M1 and Humulin M2 should be administered by subcutaneous or intramuscular injection only. Humulin S may be administered in combination with Humulin I or Humulin Zn as required. **Humulin I, Zn, M1 and M2:** Rotate vial in palms of hands immediately before use to re-suspend. **Mixing of insulins:** The shorter-acting insulin should be drawn into the syringe first, to prevent contamination of the vial by the longer-acting preparation. It is advisable to inject immediately after mixing. **Contra-indications, Warnings, etc. Contra-indications:** Hypoglycaemia. Under no circumstances should Humulin I, Humulin Zn, Humulin M1 or Humulin M2 be given intravenously. **Precautions: Usage in pregnancy:** Insulin requirements usually fall during the first trimester and increase during the second and third trimesters. **Transferring from other insulins:** A small number of patients transferring from insulins of animal origin may require a reduced dosage and/or a change in the ratio of soluble to intermediate preparations, especially if they are very tightly controlled and bordering on hypoglycaemia. The risk of hypoglycaemia can be considered minimal if the daily dosage is less than 40 IU. Insulin-resistant patients receiving more than 100 IU daily should be referred to hospital for transfer. **Side-effects:** Lipodystrophy, insulin resistance and hypersensitivity have rarely been reported. **Legal Category:** P. **Package Quantities:** 10ml glass vials in packs of 5. **Price:** Humulin S: 100 IU/ml. £6.68; Humulin I: 100 IU/ml. £6.68; Humulin Zn: 100 IU/ml. £6.68; Humulin M1: 100 IU/ml. £6.68; Humulin M2: 100 IU/ml. £6.68. **Product Licence Numbers, Name and Address:** Humulin S 100 IU/ml 0006/0165 Humulin I 100 IU/ml 0006/0168 Humulin Zn 100 IU/ml 0006/0179 Humulin M1 100 IU/ml 0006/0199 Humulin M2 100 IU/ml 0006/0200. **Date of Preparation:** January 1986.

References: 1. Corcoran, J.S. and Yudkin, J.S. Diabetic Medicine, 1985, **2**, 131-133. 2. Fineberg, S.E. *et al.* Diabetologia, 1983, **25**, 465-469.

Full Prescribing Information Available From:
Eli Lilly and Company Limited, Kingsclere Road, Basingstoke, Hampshire RG21 2XA. Telephone: Basingstoke (0256) 473241.

'HUMULIN' is a Lilly trade mark

Hu 141 March 1986

Lilly DIABETES CARE

He's running on the new M2.

He has found that a B.D. dose of the new Humulin M2 closely matches his daily insulin requirements.

The 20/80 mixture of Humulin S (soluble) and Humulin I (isophane) provides both a rapid action and prolonged effect that fit his needs.

In another patient with a lower soluble insulin requirement, Humulin M1, containing 10% soluble and 90% isophane, might be more suitable.

All this with a consistency and convenience that cannot usually be achieved with free mixing.[1]

Like all Humulin products, M1 and M2 share the unique benefits of human insulin produced by genetic engineering; low immunogenicity,[2] unlimited future supply and at a cost comparable with pork or enzymatically modified insulins.



Humulin
Human insulin (crb)
MIXTURES

Consistency and convenience with low immunogenicity

An addition to the family-

For small and fragile veins

Neoflon™ Intravenous Cannula

Neoflon™ is part of the Venflon range of I.V. Cannulae but has been specifically designed for Neonatal, small and fragile vein cannulation.

Design

The unique design of Neoflon with its detachable wing-holder makes the product, despite its small size, easy to hold and gives a Venflon type grip to ensure convenient and precise venepuncture.

Construction

Made from P.T.F.E. and with the Cannula tip tapered and bevelled insertion is facilitated with the risk of kinking and peelback minimised.

Fixing

The flexible wings facilitate secure fixation reducing the incidence of mechanical irritation.



*Article No. 1350-S

For further information please phone or write to British Viggo in Swindon.

International customers please contact Viggo International Sales.

TM Viggo Trade Mark

Viggo

British Viggo
Faraday Road
Swindon
Wiltshire SN3 5HZ

Tel: 0793 641791
Telex: 444443 VIGGO G

Viggo International Sales
Chertsey Road
Windlesham
Surrey GU20 6HJ

Tel: 0276 77222
Telex: 859363 BOC GHQ G
Fax No: 0276 71333

BOC Health Care

Effective asthma control in the pre-school child

Intal®
Sodium Cromoglycate BP
Nebuliser Solution

Prescribing Information
Presentation Ampoules containing Sodium Cromoglycate BP 20mg in 2ml sterile aqueous solution. **Uses** Preventive treatment of bronchial asthma. Also prevents the bronchoconstriction induced by exercise, cold air and chemical irritants. **Dosage and Administration** Since Intal Nebuliser Solution therapy is preventive, it is important that regular dosage is maintained, as distinct from interim therapy or use to relieve symptoms. Adults and children: the contents of one ampoule are administered by nebulisation using a suitable power operated nebuliser four times daily. In severe cases frequency of administration may be increased to 5 or 6 times daily. **Contra-indications, Warnings etc.** There are no specific contra-indications. Intal Nebuliser Solution must not be given by injection. **Side effects** Occasional irritation of the throat and in rare cases severe bronchospasm, have been reported with powder forms of Sodium Cromoglycate. **Basic NHS Cost and Product Licence Number** £9.43 per 48 × 2ml ampoules PL 0113/0068
® Registered trademark

FISONS Pharmaceuticals FISONS plc – PHARMACEUTICAL DIVISION 12 Derby Road, Loughborough, Leicestershire LE11 0BB.

Monatsschrift Kinderheilkunde

Organ der Deutschen Gesellschaft für Kinderheilkunde

134. Band
Heft 10
Oktober 1986

Springer-Verlag
Berlin Heidelberg New York London
Paris Tokyo

Indexed in Current Contents

Monatsschr Kinderheilkd (1986) 134, 10

Annual subscription: DM 278,— plus postage

Published by British Medical Association, Tavistock Square, London WC1H 9JR, and printed in England by The Devonshire Press Ltd., Torquay



Pure innovation revealed

The range of human insulins from Nordisk and Wellcome

Nordisk Wellcome

Full prescribing information available on request from either:-

Nordisk-UK	The Wellcome Foundation Ltd.
Highview House	Crewe Hall
Tattenham Crescent	Crewe
Epsom KT18 8QJ	Cheshire CW1 1UB
Tel. No: Burgh Heath (07373) 60621	Tel. No: Crewe (0270) 583151

Human
● INSULATARD
(Isophane Insulin Injection [NPH], highly purified human insulin [emp])

Human
● VELOSULIN
(Neutral Insulin Injection, highly purified human insulin [emp])

Human
● MIXTARD 30/70
(Neutral suspension comprising 30% Neutral Insulin Injection and 70% Isophane Insulin Injection [NPH] – human insulin [emp])

Human
● INITARD 50/50
(Neutral suspension comprising 50% Neutral Insulin Injection and 50% Isophane Insulin Injection [NPH] – human insulin [emp])

INITARD 50/50 (Neutral Suspension comprising 50% Neutral Insulin Injection and 50% Isophane Insulin Injection [NPH]). HUMAN VELOSULIN, HUMAN INSULATARD, HUMAN MIXTARD 30/70 and HUMAN INITARD 50/50 are manufactured from highly purified human insulin (emp). **PRESENTATION** HUMAN VELOSULIN, HUMAN INSULATARD, HUMAN MIXTARD 30/70 and HUMAN INITARD 50/50 are available in 10ml vials containing 100iu/ml. To provide sensory identification the metal sealing rings of the vial have tactile marks and the vials are also fitted with colour coded tamper-proof caps. **USES** Treatment of Insulin Dependent Diabetics. Human Velosulin is particularly suitable in the treatment of diabetic coma and precoma. **DOSAGE AND ADMINISTRATION** Dosage to be determined by the physician, according to the needs of the patient. Avoid accidental intra-vascular injection. **CONTRA-INDICATIONS AND WARNINGS** Insulin is contra-indicated in hypoglycaemia. In the event of overdosage, glucose should be given either orally or intravenously. Glucagon may also be administered. Human Insulatard, Human Mixtard 30/70, Human Initard 50/50, should not be given intravenously or intravascularly. Treatment with cortico-steroids, oral contraceptives or thyroid hormones may lead to an increase in dosage requirements. Beta-blockers may affect insulin requirements and mask hypoglycaemia. U100 insulin must only be used in U100 syringes. **PHARMACEUTICAL PRECAUTION** Store at 2 to 8 degrees C, protected from sunlight. Do not freeze. **LEGAL CATEGORY** P **BASIC NHS PRICE** HUMAN VELOSULIN, HUMAN INSULATARD, HUMAN MIXTARD 30/70 and HUMAN INITARD 50/50: 10 ml vial £6.95. **PRODUCT LICENCE NUMBERS** Human Velosulin 3132/0031 and 0003/0211. Human Insulatard 3132/0034 and 0003/0212. Human Mixtard 30/70 3132/0037 and 0003/0213. Human Initard 50/50 3132/0040 and 0003/0214.